Come join others currently navigating treatment in our weekly Zoom Meetup! Register here: Tuesdays, 1pm ET.

FDA Approves Kisqali for Early-Stage Breast Cancer

FDA Approves Kisqali for Early-Stage Breast Cancer

September 17, 2024

Kisqali (chemical name: ribociclib) can now be used after surgery in combination with an aromatase inhibitor to treat stage II or stage III hormone receptor-positive, HER2-negative breast cancer with a high risk of recurrence. Read more…